Ascendis Pharma A/S Logo

Ascendis Pharma A/S

Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.

ASND | US

Overview

Corporate Details

ISIN(s):
US04351P1012
LEI:
Country:
United States of America
Address:
TUBORG BOULEVARD 12, 0 HELLERUP
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ascendis Pharma A/S, founded in 2007, is a global biopharmaceutical company applying its proprietary TransCon® technology platform to develop innovative therapies for unmet medical needs. The company aims to build a leading, fully integrated biopharmaceutical business focused on making a meaningful difference in patients' lives. Its primary therapeutic areas of focus include endocrinology, rare diseases, and oncology. The development pipeline features multiple product candidates, including three in clinical development for rare endocrinological diseases and several assets in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ascendis Pharma A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ascendis Pharma A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ascendis Pharma A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America PMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.